Skip to content
TopicTracker
来自 HackerNews查看原文
译文语言译文语言

Anthropic launches AI drug discovery program

Anthropic has launched a new AI-powered drug discovery program, aiming to accelerate pharmaceutical research and development. The initiative leverages Claude's advanced capabilities to analyze complex biological data, identify potential drug candidates, and streamline the preclinical research process.

背景速读

- **Anthropic** 是一家美国 AI 公司(由前 OpenAI 员工创立),主打“安全、负责任”的大语言模型,其旗舰模型是 Claude 系列。公司因强调 AI 对齐(让 AI 符合人类意图)而知名。 - 这项新项目名为 **Claude Science**,是 Anthropic 首次涉足 **AI 药物发现**领域——即利用 AI 模型预测分子结构、加速新药研发流程。过去这类尝试多由谷歌 DeepMind(AlphaFold)等公司主导。 - 此举的背景是:全球制药业正积极试水 AI 降低研发成本(开发一种新药平均需 10 年以上、花费数十亿美元)。Anthropic 入场意味着 Claude 不再只是聊天/编程工具,而是瞄准了科学研究的垂直应用。 - 值得注意的背景:Anthropic 此前主要面向企业客户和开发者,而非生命科学垂直领域。这一动作表明该公司在寻求大语言模型在盈利空间更大的专业场景中的落地。

相关报道

  • The Wall Street Journal reported that Anthropic is approaching its first profitable quarter, with revenue expected to more than double to $10.9 billion in Q2, driven by explosive growth. The article examines the claim of operating profit (EBITDA) profitability.

  • President Trump has reportedly asked Anthropic, the AI safety company behind Claude, to undertake a task that may be technically or ethically impossible, raising questions about the future direction of AI regulation and corporate responsibility.